Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRA_10972
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
CRA_10972 is a synthetic small molecule belonging to the class of phenylbenzimidazoles[1][2]. It has the chemical formula C18H19ClN4O2[2]. The compound has been studied as a highly selective inhibitor for S1 sites of trypsin-like serine proteases, which are enzymes involved in various physiological and pathological processes[9]. Its primary mechanism is believed to be inhibition of serine protease activity, but there is no evidence it has advanced beyond preclinical or early investigative stages. There are no approved therapeutic indications or marketed formulations for this compound.
- Other names
- RTSLVPMQUZXPBZ-UHFFFAOYSA-N
02
Targets
PRSS1 (Trypsin family)
Beyond the preview
Go deeper on CRA_10972.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRA_10972.